Our latest news
Jul 21, 2021 Press ReleasesViaCyte Appoints Dr. Jon Wilensky as Head of Surgery
Read MoreSign up for updates
To have our press releases and major updates sent to you, please provide your name and email address.
ViaCyte has multiple key relationships with advocacy organizations. These groups have supported the research and development of ViaCyte’s breakthrough cell replacement product candidates for insulin-requiring diabetes. If you would like more information on collaborating with ViaCyte, please contact us for further information.
Stem cell research and development at ViaCyte is seeking to change the way type 1 diabetes is treated. The video was produced by CIRM.
The California Institute for Regenerative Medicine (CIRM) has awarded grants and loans totaling more than $72M to advance ViaCyte’s development of stem cell-based therapies for diabetes, and for other related stem cell research. CIRM was funded by California’s Proposition 71: the California Stem Cell Research and Cures Initiative.
Visit Website
JDRF provides scientific, financial, and advocacy support for ViaCyte’s research efforts and numerous ViaCyte collaborators.
Visit Website
By leveraging the power of social media and technology, Beyond Type 1 creates and funds a portfolio of the most promising global efforts working to educate, advocate, and eventually cure type 1 diabetes. Beyond Type 1 provides both financial and social support for the development of ViaCyte’s diabetes product candidates.
Visit WebsiteViaCyte Appoints Dr. Jon Wilensky as Head of Surgery
Read MoreTo have our press releases and major updates sent to you, please provide your name and email address.
Type on the line above then press the Enter/Return key to submit a new search query